Clinical Trial of Autologous B7-H3 CAR T Cells in Reoccurent Platinum-resistant Ovarian Tumors

This study is testing an experimental CAR-T cell therapy — where a patient's own immune cells are reprogrammed to target a protein called B7-H3 — for women with ovarian cancer that has come back and is no longer responding to platinum-based chemotherapy. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with ovarian cancer (most types of epithelial ovarian cancer are eligible) - You have received at least one platinum-based chemotherapy regimen and your cancer is now platinum-resistant or platinum-refractory (meaning it came back or did not respond) - You have at least one measurable tumor - You are in reasonably good physical condition (ECOG score 0–2) - You have a life expectancy of at least 3 months - You are willing to provide a tumor tissue sample **You may NOT be eligible if...** - You have pure sarcoma, stromal, or germ cell ovarian tumor - You are in very poor general health - You have significant unresolved toxicity from prior treatments - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.